Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -338.7%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $920195 | $2M | $3M | $13M | $70M | $62M | $147M | $5M | $15M | — | — |
| Enterprise Value | $-6910660 | $-6198578 | $2M | $6M | $49M | $23M | $120M | $3M | $7M | — | — |
| P/E Ratio → | -0.03 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.07 | 0.21 | 2.11 | 1.70 | 3.12 | 1.49 | 4.77 | 1.70 | 1.71 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -338.7% | -338.7% | -467.2% | -207.9% | -74.7% | -57.2% | -105.7% | -179.0% | -265.8% | -322.8% | -409.4% |
| ROA | -227.2% | -227.2% | -285.4% | -172.6% | -69.9% | -55.7% | -102.8% | -166.4% | -235.0% | -209.1% | -356.1% |
| ROIC | -15565.8% | -15565.8% | -4555.2% | -2331.3% | -900.7% | -496.5% | -583.4% | -1149.5% | -2202.1% | -1010.3% | -3403.9% |
| ROCE | -323.1% | -323.1% | -468.6% | -209.3% | -75.0% | -57.3% | -105.8% | -179.5% | -265.6% | -322.6% | -409.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | 0.01 | 0.47 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.98 | -0.99 | -0.91 | -0.94 | -0.94 | -0.88 | -0.66 | -0.96 | 0.09 | -0.99 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -20.93 | -20.93 | — | — | — | — | — | — | -324.74 | -1752.56 | — |
Net cash position: cash ($8M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.84 | 3.84 | 0.83 | 2.31 | 7.64 | 24.69 | 68.15 | 5.83 | 22.81 | 0.23 | 5.74 |
| Quick Ratio | 3.84 | 3.84 | 0.83 | 2.31 | 7.64 | 24.69 | 61.47 | 4.26 | 22.81 | 0.23 | 5.74 |
| Cash Ratio | 3.60 | 3.60 | 0.64 | 2.07 | 7.46 | 24.37 | 60.61 | 3.92 | 22.18 | 0.19 | 5.61 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | 0.01 | 0.02 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 100.0% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $932730 | $80119 | $27355 | $23977 | $23549 | $17761 | $8014 | $6886 | $5750 | $5417 |
Liquidity and dilution risk
Based on current market data, Genprex trades at a price-to-book ratio of 0.06, which, as reported in financial statements, reflects a deep discount compared to peers like Immunovant, suggesting the market assigns minimal terminal value to the company's current intellectual property and clinical-stage pipeline assets.
The extremely low P/B ratio indicates that investors are pricing the company primarily on its liquidation value rather than its potential for future earnings. This valuation suggests that the market remains highly skeptical of the clinical success of the REQORSA program, viewing the current equity as a high-risk option on future trial readouts.
According to historical financial data, Genprex has consistently generated negative ROIC, with figures reaching -33.3% in 2024Q4, illustrating that the company is currently destroying invested capital as it funds high-cost clinical trials without any offsetting commercial revenue or operational margin generation.
The persistent negative return on capital is a structural feature of the company's pre-revenue status, where every dollar invested is consumed by R&D rather than deployed into productive, return-generating assets. Investors should monitor whether future clinical milestones can eventually justify this capital destruction by providing a pathway to commercialization.
As reported in recent SEC filings, the company's current ratio has fluctuated wildly from 0.67 in 2025Q3 to 5.61 in 2026Q1, highlighting a precarious liquidity position that remains entirely dependent on the timing of dilutive equity financing rather than stable, internally generated working capital.
The extreme variance in the current ratio suggests that the company's ability to meet short-term obligations is highly sensitive to the timing of capital raises. This lack of liquidity stability warrants further investigation into the company's ability to maintain clinical trial momentum without resorting to increasingly dilutive financing structures.
Based on standard financial analysis, the use of P/E ratios to evaluate Genprex is fundamentally flawed, as the company's negative earnings and lack of revenue render traditional valuation multiples meaningless for assessing the true economic potential of its non-viral gene delivery platform.
Investors should instead focus on the cash burn rate and the progress of clinical trial enrollment as primary indicators of value. Applying P/E or EV/EBITDA metrics to a pre-revenue biotech firm obscures the reality that the company is a venture-style investment rather than a mature, earnings-driven enterprise.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GNPX stock.
Genprex, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Genprex, Inc.'s return on equity (ROE) is -338.7%. The historical average is -245.5%.
Based on historical data, Genprex, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.